Lauren Brown, M.D.

Samuel H. Selesnick, M.D., F.A.C.S. is Professor and Vice Chair of the Department of Otolaryngology and Professor of Otolaryngology in Neurological Surgery at the Weill Cornell Medical College, and is a member of the Department of Neurological Surgery at Memorial Sloan Kettering Cancer Center.Dr. Selesnick is the Editor-in-Chief of The Laryngoscope, which is the oldest and largest otolaryngology peer reviewed journal. Dr. Selesnick is a Past President of the American Otological Society and is a Past President of the American Neurotology Society, the largest specialty organization of neurotologists - skull base surgeons in the United States. Dr. Selesnick is the General Secretary of the International Society for Otology (The Politzer Society). Neurotology encompasses lateral skull base surgery for tumors such as vestibular schwanommas (acoustic neuromas), meningiomas,epidermoid tumors and glomus tumors, as well as the surgical and medical treatment for patients suffering from complex ear-related problems such as hearing loss, otosclerosis, cholesteatoma and facial nerve tumors.Dr. Selesnick has lectured on neurotologic and ear related topics in the United States, France, Italy, the United Kingdom, Austria, Denmark, Spain, the Czech Republic, Croatia, Greece, Poland, Australia, Japan, Israel, the United Arab Emirates, Qatar, India, the Ukraine, Canada, Brazil and MexicoDr. Selesnick has received The Certificate of Honor bestowed by The American Academy of Otolaryngology-Head and Neck Surgery, and has been named one of the best doctors in his field by lay publications. Dr. Selesnick sits on the editorial board of the journal 'Otology and Neurotology' and has served as guest editor of 'The Otolaryngologic Clinics of North America'. Dr. Selesnick has served on the Executive Council of The American Neurotology Society, and has served on or chaired numerous committees for the American Academy of Otolaryngology-Head and Neck Surgery, The American Otological Society, The Triological Society, The American College of Surgeons and other medical societies. Dr. Selesnick serves on the Board of Directors of the American Academy of Otolaryngology - Head and Neck Surgery.Dr. Selesnick has researched topics in neurotology - skull base surgery and otology, and has published extensively in peer reviewed journals. The second book he has co-edited was released in November 2010.At the NewYork-Presbyterian Hospital/Weill Cornell Medical Center, Dr. Selesnick has pioneered skull base surgery for acoustic neuromas and meningiomas as well as other skull base lesions. He has pioneered the use of lasers for the treatment of hearing loss in otosclerosis, and for the treatment of cholesteatoma, during mastoidectomy surgery and for tympanoplasty to repair tympanic membrane perforation.Dr. Selesnick received a Bachelor of Arts from Wesleyan University and graduated from the New York University School of Medicine. He completed his training in Otolaryngology at The Manhattan Eye, Ear, and Throat Hospital - Cornell Residency Program and went on to advanced Fellowship training in Otology, Neurotology, and Skull Base Surgery at The University of California, San Francisco. Dr. Selesnick has been frequently interviewed by the television, radio, and print media. He is an Honorary Police Surgeon in the New York Police Department.His website address is http://www.weillcornell.org/physician/samuelselesnick/index.html."The Acoustic Neuroma Association would like to thank the Weill Cornell Medicine Department of Neurological Surgery for partnering with the ANA as a Gold sponsor."To learn more about ANA please click the below link: https://www.anausa.org

Dr. Kimberly Sippel attended Harvard College in Cambridge, Massachusetts, graduating with honors in Biochemical Sciences. She received her medical degree with the Alpha Omega Alpha honor distinction from the Columbia University College of Physicians & Surgeons in New York City. Following two years of training in general surgery at the Massachusetts General Hospital, Dr. Sippel completed ophthalmology residency training at the Massachusetts Eye and Ear Infirmary, Harvard Medical School. She then completed the fellowship program in Cornea and External Disease at the Massachusetts Eye and Ear Infirmary, and is a recipient of both a Heed Foundation fellowship, as well as the American Ophthalmological Society Knapp Foundation fellowship award. Dr. Sippel also pursued several years of vision-related laboratory investigation as a Research Fellow at both the Massachusetts Eye and Ear Infirmary and the Schepens Eye Research Institute in Boston, Massachusetts. Dr. Sippel is a diplomate of the American Board of Ophthalmology. Dr. Sippel is an Assistant Professor of Ophthalmology at the Weill Cornell Medicine and the NewYork Presbyterian Hospital. Prior to joining the Weill Cornell faculty, Dr. Sippel was with Cornea Consultants of Boston/ Laser Eye Consultants of Boston and had an active teaching role at Massachusetts Eye & Ear Infirmary. Her interests include laser vision correction surgery, corneal transplantation and cataract surgery, corneal disease and dry eye, and conjunctival tumors.Kimberly C. Sippel, M.D. discusses the specifics of the cornea.

Paul Chapman, MD is currently the Chief Medical Research Officer for the Meyer Cancer Center at Weill Cornell Medicine and NewYork-Presbyterian Hospital. Dr. Chapman received his M.D. degree from Weill Cornell Medical College in 1981 and trained in internal medicine as an intern and resident at the University of Chicago Hospitals and Clinics from 1981-1984. After that, he returned to New York as a medical oncology Fellow at Memorial Sloan Kettering Cancer where he focused on immunotherapy of melanoma in the laboratory of Dr. Alan Houghton. He joined the faculty of Memorial Sloan Kettering Cancer Center (MSKCC) in 1988 and worked there through 2023 as a tenured Attending Physician. During this time at MSKCC, Dr. Chapman led many clinical and laboratory studies designed to develop new and improved treatments for melanoma. This included the first BRAF targeted therapy trial and several immunotherapy trials. His research continues to focus on developing new treatments for melanoma.